Bibliographie (2530)
Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.
jeudi, 14 octobre 2021 12:40 Écrit par Zouhair SouissiShort-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review – JAMA Network Open Commentaries: Most COVID-19 survivors have symptoms 6 months on, review finds – CIDRAP Expert reaction to systematic review on rates of postacute sequelae of SARS-CoV-2 infection (PASC) – Science Media Centre How many people get ‘long COVID’? More […]
The post Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection. appeared first on Links Medicus.
![[Preprint] In RCT with 29,949 participants, the Novavax vaccine demonstrated high overall efficacy (>90%) for the prevention of Covid-19, and all moderate-to-severe cases occurred in placebo recipients.](/media/k2/items/cache/2acc95c7f6cdfc7af285b1c747c52cfd_L.jpg)
[Preprint] In RCT with 29,949 participants, the Novavax vaccine demonstrated high overall efficacy (>90%) for the prevention of Covid-19, and all moderate-to-severe cases occurred in placebo recipients.
jeudi, 14 octobre 2021 12:40 Écrit par Zouhair SouissiEfficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico – medRxiv Commentary: Novel vaccine demonstrates high efficacy for prevention of COVID-19 – News Medical Related: RCT: Novavax vaccine conferred 89.7% protection against symptomatic SARS-CoV-2 infection and 100% protection against hospitalizations or deaths. Opinion | The mRNA vaccines are extraordinary, but Novavax […]
The post [Preprint] In RCT with 29,949 participants, the Novavax vaccine demonstrated high overall efficacy (>90%) for the prevention of Covid-19, and all moderate-to-severe cases occurred in placebo recipients. appeared first on Links Medicus.
Seroconversion and fever are dose-dependent in a nonhuman primate model of inhalational COVID-19.
mercredi, 13 octobre 2021 05:12 Écrit par Zouhair SouissiSeroconversion and fever are dose-dependent in a nonhuman primate model of inhalational COVID-19 – PLOS Pathogens Commentary: Dose-dependent COVID-19 symptoms – Nature Reviews Microbiology Commentaries on Twitter When exposed to #SARSCoV2 why does one person have no illness, while another is soon in ICU?Dose.Controlled study in monkeys shows the dose of viruses inhaled is […]
The post Seroconversion and fever are dose-dependent in a nonhuman primate model of inhalational COVID-19. appeared first on Links Medicus.
A primer on what we know about mixing and matching Covid vaccines.
mercredi, 13 octobre 2021 05:12 Écrit par Zouhair SouissiA primer on what we know about mixing and matching Covid vaccines – STAT Related: Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination. RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. Another study shows increased immune response with […]
The post A primer on what we know about mixing and matching Covid vaccines. appeared first on Links Medicus.
WHO advisers recommend 3rd COVID vaccine dose for highest-risk groups.
mercredi, 13 octobre 2021 05:12 Écrit par Zouhair SouissiWHO advisers recommend 3rd COVID vaccine dose for highest-risk groups – CIDRAP See also: WHO advises additional COVID shot for immunocompromised people – Reuters
The post WHO advisers recommend 3rd COVID vaccine dose for highest-risk groups. appeared first on Links Medicus.
How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.
mardi, 12 octobre 2021 02:29 Écrit par Zouhair SouissiHow antiviral pill molnupiravir shot ahead in the COVID drug hunt – Nature Related: What we know — and don’t know — about Merck’s new Covid-19 pill. [Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with […]
The post How antiviral pill Molnupiravir shot ahead in the COVID drug hunt. appeared first on Links Medicus.
Cluster RCT: An antimicrobial stewardship intervention safely reduced the use of broad-spectrum antibiotics among patients hospitalized with moderately severe community-acquired pneumonia.
mardi, 12 octobre 2021 02:29 Écrit par Zouhair SouissiNarrow-spectrum antibiotics for community-acquired pneumonia in Dutch adults (CAP-PACT): a cross-sectional, stepped-wedge, cluster-randomised, non-inferiority, antimicrobial stewardship intervention trial – The Lancet Infectious Diseases (link to abstract – $ for full-text)
The post Cluster RCT: An antimicrobial stewardship intervention safely reduced the use of broad-spectrum antibiotics among patients hospitalized with moderately severe community-acquired pneumonia. appeared first on Links Medicus.
D-Dimer testing for the exclusion of pulmonary embolism has limited clinical utility among hospitalized patients with COVID-19 – most patients with or without pulmonary embolism have increased levels.
mardi, 12 octobre 2021 02:29 Écrit par Zouhair SouissiD-Dimer Testing for the Exclusion of Pulmonary Embolism Among Hospitalized Patients With COVID-19 – JAMA Network Open Commentary: D-Dimer Level Not Useful for Ruling Out PE in COVID-19 Patients – HealthDay
The post D-Dimer testing for the exclusion of pulmonary embolism has limited clinical utility among hospitalized patients with COVID-19 – most patients with or without pulmonary embolism have increased levels. appeared first on Links Medicus.
Why easing COVID restrictions could prompt a fierce flu rebound – “As pandemic restrictions ease, other respiratory viruses are returning in unexpected ways”.
mardi, 12 octobre 2021 02:29 Écrit par Zouhair SouissiWhy easing COVID restrictions could prompt a fierce flu rebound – Nature
The post Why easing COVID restrictions could prompt a fierce flu rebound – “As pandemic restrictions ease, other respiratory viruses are returning in unexpected ways”. appeared first on Links Medicus.
RCT: No benefit from antithrombotic therapy (aspirin or apixaban) in outpatients with clinically stable symptomatic COVID-19.
mardi, 12 octobre 2021 02:29 Écrit par Zouhair SouissiEffect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial – JAMA Editorial: Antithrombotic Therapy for Outpatients With COVID-19: Implications for Clinical Practice and Future Research – JAMA Commentary on Twitter Data do not support the use of aspirin or apixaban in the outpatient setting […]
The post RCT: No benefit from antithrombotic therapy (aspirin or apixaban) in outpatients with clinically stable symptomatic COVID-19. appeared first on Links Medicus.
